Charles River Associates (CRA) Names Patrick Hillan Vice President, Expanding Life Sciences Commercial Strategy Expertise

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced the addition of Patrick Hillan as a Vice President in the firm’s Life Sciences Practice.

“I am happy to welcome Patrick to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He has deep expertise in medical affairs strategy, having partnered with global pharmaceutical and biotechnology companies across a broad range of therapeutic areas to generate actionable stakeholder insights, develop evidence-based strategies, and support successful product launches worldwide.”

“Patrick’s expertise in medical affairs will be instrumental as we continue to enhance and scale our life sciences advisory services,” said Dr. Gregory K. Bell, CRA Group Vice President and Life Sciences Practice Leader. “His ability to translate stakeholder insights, scientific evidence, and evolving market dynamics into actionable medical strategies will strengthen the support we provide to medical affairs teams, while helping clients make informed decisions to support successful launches, and maximize the value of their innovations.”

Prior to joining CRA, Mr. Hillan was a partner at a life sciences consulting firm, where he advised pharmaceutical and biotechnology companies on medical affairs strategy and launch readiness across a broad range of therapeutic areas. He led engagements spanning healthcare professional and patient insight generation, strategic and tactical planning, integrated evidence generation planning, and scientific platform and narrative development, helping organizations build the scientific and strategic foundations needed to support successful product launches and optimize asset value throughout the product lifecycle.

Mr. Hillan holds a MSc in Neuroscience and a BSc in Biological Sciences from the University of Edinburgh.

About CRA’s Life Sciences Practice
CRA’s Life Sciences Practice works with leading biotech, medical device, and pharmaceutical companies; law firms; regulatory agencies; and national and international industry associations. We provide the analytical expertise and industry experience needed to address our clients’ toughest issues. We have a reputation for rigorous and innovative analysis, careful attention to detail, and the ability to work effectively as part of a wider team of advisers.

About Charles River Associates (CRA)
Charles River Associates^® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Instagram, and Facebook.

SAFE HARBOR STATEMENT
Statements in this press release concerning the addition of Patrick Hillan, the expansion of CRA’s Life Sciences Practice, and any future business Mr. Hillan may generate for CRA, are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others: the failure to generate engagements for us; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition. Additional potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.